<DOC>
	<DOCNO>NCT01947946</DOCNO>
	<brief_summary>The purpose study determine whether Benralizumab reduce number asthma exacerbation patient remain uncontrolled medium dose ICS-LABA .</brief_summary>
	<brief_title>Efficacy Safety Study Benralizumab Added Medium-dose Inhaled Corticosteroid Plus LABA Patients With Uncontrolled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Female male age 18 75 year , inclusively 3 . History physiciandiagnosed asthma require treatment medium dose ICS ( &gt; 250ug fluticasone dry powder formulation equivalent total daily dose ) LABA , least 12 month prior Visit 1 4 . Documented treatment mediumdose ICS ( &gt; 250ug â‰¤500ug fluticasone dry powder formulation equivalent total daily dose ) LABA least 3 month prior Visit 1 Exclusion criterion : 1 . Clinically important pulmonary disease asthma ( e.g . active lung infection , COPD , bronchiectasis , pulmonary fibrosis , cystic fibrosis , hypoventilation syndrome associate obesity , lung cancer , alpha 1 antitrypsin deficiency , primary ciliary dyskinesia ) ever diagnose pulmonary systemic disease , asthma , associate elevated peripheral eosinophil count ( e.g . allergic bronchopulmonary aspergillosis/mycosis , Churg Strauss syndrome , hypereosinophilic syndrome ) 2 . Any disorder , include , limited , cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , haematological , psychiatric , major physical impairment stable opinion Investigator could : Affect safety patient throughout study Influence finding study interpretation Impede patient 's ability complete entire duration study 3 . Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior date informed consent obtain screening/runin period 4 . Any clinically significant abnormal finding physical examination , vital sign , haematology , clinical chemistry , urinalysis screening/runin period , opinion Investigator , may put patient risk his/her participation study , may influence result study , patient 's ability complete entire duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Asthma , Bronchial Diseases , Respiratory Tract Diseases , Lung Diseases , Obstructive Lung Diseases</keyword>
</DOC>